Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients - PubMed

Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients

T Aoyama et al. J Clin Invest. 1995 Jun.

Abstract

Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) was purified from human liver. The molecular masses of the native enzyme and the subunit were estimated to be 154 and 70 kD, respectively. The enzyme was found to catalyze the major part of mitochondrial palmitoylcoenzyme A dehydrogenation in liver, heart, skeletal muscle, and skin fibroblasts (89-97, 86-99, 96-99, and 78-87%, respectively). Skin fibroblasts from 26 patients suspected of having a disorder of mitochondrial beta-oxidation were analyzed for VLCAD protein using immunoblotting, and 7 of them contained undetectable or trace levels of the enzyme. The seven deficient fibroblast lines were characterized by measuring acyl-coenzyme A dehydrogenation activities, overall palmitic acid oxidation, and VLCAD protein synthesis using pulse-chase, further confirming the diagnosis of VLCAD deficiency. These results suggested the heterogenous nature of the mutations causing the deficiency in the seven patients. Clinically, all patients with VLCAD deficiency exhibited cardiac disease. At least four of them presented with hypertrophic cardiomyopathy. This frequency (> 57%) was much higher than that observed in patients with other disorders of mitochondrial long-chain fatty acid oxidation that may be accompanied by cardiac disease in infants.

Similar articles

• Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.

  Djouadi F, Aubey F, Schlemmer D, Ruiter JP, Wanders RJ, Strauss AW, Bastin J. Djouadi F, et al. Hum Mol Genet. 2005 Sep 15;14(18):2695-703. doi: 10.1093/hmg/ddi303. Epub 2005 Aug 22. Hum Mol Genet. 2005. PMID: 16115821

• A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase.

  Aoyama T, Uchida Y, Kelley RI, Marble M, Hofman K, Tonsgard JH, Rhead WJ, Hashimoto T. Aoyama T, et al. Biochem Biophys Res Commun. 1993 Mar 31;191(3):1369-72. doi: 10.1006/bbrc.1993.1368. Biochem Biophys Res Commun. 1993. PMID: 8466512

• Neonatal screening for very long-chain acyl-coA dehydrogenase deficiency: enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine levels.

  Liebig M, Schymik I, Mueller M, Wendel U, Mayatepek E, Ruiter J, Strauss AW, Wanders RJ, Spiekerkoetter U. Liebig M, et al. Pediatrics. 2006 Sep;118(3):1065-9. doi: 10.1542/peds.2006-0666. Pediatrics. 2006. PMID: 16950999

• Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship.

  Gregersen N, Andresen BS, Corydon MJ, Corydon TJ, Olsen RK, Bolund L, Bross P. Gregersen N, et al. Hum Mutat. 2001 Sep;18(3):169-89. doi: 10.1002/humu.1174. Hum Mutat. 2001. PMID: 11524729 Review.

Cited by

• The Physiological and Pathological Role of Acyl-CoA Oxidation.

  Szrok-Jurga S, Czumaj A, Turyn J, Hebanowska A, Swierczynski J, Sledzinski T, Stelmanska E. Szrok-Jurga S, et al. Int J Mol Sci. 2023 Oct 3;24(19):14857. doi: 10.3390/ijms241914857. Int J Mol Sci. 2023. PMID: 37834305 Free PMC article. Review.

• Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARα deterioration.

  Takahashi K, Kamijo Y, Hora K, Hashimoto K, Higuchi M, Nakajima T, Ehara T, Shigematsu H, Gonzalez FJ, Aoyama T. Takahashi K, et al. Toxicol Appl Pharmacol. 2011 May 1;252(3):237-49. doi: 10.1016/j.taap.2011.02.012. Epub 2011 Feb 19. Toxicol Appl Pharmacol. 2011. PMID: 21338618 Free PMC article.

• Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress.

  Okiyama W, Tanaka N, Nakajima T, Tanaka E, Kiyosawa K, Gonzalez FJ, Aoyama T. Okiyama W, et al. J Hepatol. 2009 Jun;50(6):1236-46. doi: 10.1016/j.jhep.2009.01.025. Epub 2009 Apr 2. J Hepatol. 2009. PMID: 19398233 Free PMC article.

• Compared effects of missense mutations in Very-Long-Chain Acyl-CoA Dehydrogenase deficiency: Combined analysis by structural, functional and pharmacological approaches.

  Gobin-Limballe S, McAndrew RP, Djouadi F, Kim JJ, Bastin J. Gobin-Limballe S, et al. Biochim Biophys Acta. 2010 May;1802(5):478-84. doi: 10.1016/j.bbadis.2010.01.001. Epub 2010 Jan 12. Biochim Biophys Acta. 2010. PMID: 20060901 Free PMC article.

• The First Reported Case of a Child with Two Different Rare Metabolic Disorders: Very Long-Chain Acyl-CoA Dehydrogenase Deficiency and Encephalomyopathic Mitochondrial DNA Depletion Syndrome 13.

  Alotaibi M, Alqasmi A, Albassam F, Alkahtani T, Alqahtany M, Alkhaldi M. Alotaibi M, et al. Glob Med Genet. 2023 Oct 10;10(4):278-281. doi: 10.1055/s-0043-1775979. eCollection 2023 Dec. Glob Med Genet. 2023. PMID: 37822418 Free PMC article.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Society for Clinical Investigation
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • BioCyc
  • GlyGen glycoinformatics resource
  • Mouse Genome Informatics (MGI)

• Miscellaneous

  • NCI CPTAC Assay Portal